Non-alcoholic fatty liver disease and thyroid dysfunction: A systematic review

World Journal of Gastroenterology

Volumn 20, Issue 25, 2014, Pages 8102-8109

  Eshraghian, Ahad ^a   Jahromi, Alireza Hamidian ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Louisiana State University Health Sciences Center   (United States)

Author keywords

Hypothyroidism; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Pathophysiology; Risk factor; Thyroid dysfunction

Indexed keywords

CHOLESTEROL; FATTY ACID; FIBROBLAST GROWTH FACTOR 21; LEPTIN; LIPOPROTEIN LIPASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; THYROTROPIN; TRIACYLGLYCEROL; LIOTHYRONINE; THYROID HORMONE RECEPTOR BETA; THYROXINE; THYROID HORMONE;

CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; IMMUNORADIOMETRIC ASSAY; INSULIN RESISTANCE; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK FACTOR; SCIENTIFIC LITERATURE; SUBCLINICAL HYPOTHYROIDISM; SYSTEMATIC REVIEW; BILIARY CIRRHOSIS; CHEMILUMINESCENCE IMMUNOASSAY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; KUPFFER CELL; LIPID BLOOD LEVEL; OXIDATIVE STRESS; SCLEROSING CHOLANGITIS; THYROID DISEASE; THYROID HORMONE BLOOD LEVEL; ANIMAL; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; THYROID DISEASES; THYROID GLAND;

ANIMALS; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; THYROID DISEASES; THYROID GLAND; THYROID HORMONES;

EID: 84903954886     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i25.8102     Document Type: Review

References (69)

1. Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis 2010; 14: 591-604 [PMID: 21055684 DOI: 10.1016/ j.cld.2010.07.006]
2. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-889 [PMID: 17402991]
3. Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med 2011; 11: 176-178 [PMID: 21526706]
4. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007; 6: 161-163 [PMID: 17786142]
5. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care 2012; 35: 873-878 [PMID: 22374640 DOI: 10.2337/dc11-1849]
6. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010; 25: 352-356 [PMID: 19817963 DOI: 10.1111/j.1440-1746.2009.05998.x]
7. Caldwell SH, Lee VD, Kleiner DE, Al-Osaimi AM, Argo CK, Northup PG, Berg CL. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol 2009; 8: 346-352 [PMID: 20009134]
8. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG, Psyrogiannis AI, Kalfarentzos FE, Kyriazopoulou VE. Thyroid function in humans with morbid obesity. Thyroid 2006; 16: 73-78 [PMID: 16487017]
9. Raftopoulos Y, Gagné DJ, Papasavas P, Hayetian F, Maurer J, Bononi P, Caushaj PF. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004; 14: 509-513 [PMID: 15130228]
10. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, Bremner A, Maisonneuve P, Sgarbi JA, Khaw KT, Vanderpump MP, Newman AB, Cornuz J, Franklyn JA, Westendorp RG, Vittinghoff E, Gussekloo J. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304: 1365-1374 [PMID: 20858880 DOI: 10.1001/jama.2010.1361]
11. Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. Int J Obes Relat Metab Disord 2000; 24 Suppl 2: S109-S112 [PMID: 10997623]
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100 [PMID: 19621070 DOI: 10.1371/journal. pmed.1000100]
13. Chung GE, Kim D, Kim W, Yim JY, Park MJ, Kim YJ, Yoon JH, Lee HS. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012; 57: 150-156 [PMID: 22425701 DOI: 10.1016/j.jhep.2012.02.027]
14. Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol 2003; 37: 340-343 [PMID: 14506393]
15. Silveira MG, Mendes FD, Diehl NN, Enders FT, Lindor KD. Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int 2009; 29: 1094-1100 [PMID: 19291181 DOI: 10.1111/ j.1478-3231.2009.02003.x]
16. Pagadala MR, Zein CO, Dasarathy S, Yerian LM, Lopez R, McCullough AJ. Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57: 528-534 [PMID: 22183820 DOI: 10.1007/s10620-011-2006-2]
17. Xu C, Xu L, Yu C, Miao M, Li Y. Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese. Clin Endocrinol (Oxf) 2011; 75: 240-246 [PMID: 21521285 DOI: 10.1111/j.1365-2265.2011.04016.x]
18. Mazo DF, Lima VM, Stefano JT, Rabelo F, Faintuch J, Oliveira CP. Gluco-lipidic indices in treated hypothyroidism associated with nonalcoholic fatty liver disease. Arq Gastroenterol 2011; 48: 186-189 [PMID: 21952703]
19. Moustafa AH, Ali EM, Mohamed TM, Abdou HI. Oxidative stress and thyroid hormones in patients with liver diseases. Eur J Intern Med 2009; 20: 703-708 [PMID: 19818291 DOI: 10.1016/j.ejim.2009.08.003]
20. Carulli L, Ballestri S, Lonardo A, Lami F, Violi E, Losi L, Bonilauri L, Verrone AM, Odoardi MR, Scaglioni F, Bertolotti M, Loria P. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med 2013; 8: 297-305 [PMID: 21559749 DOI: 10.1007/s11739-011-0609-4]
21. Zhang J, Sun H, Chen L, Zheng J, Hu X, Wang S, Chen T. Relationship between serum TSH level with obesity and NAFLD in euthyroid subjects. J Huazhong Univ Sci Technolog Med Sci 2012; 32: 47-52 [PMID: 22282244 DOI: 10.1007/ s11596-012-0008-8]
22. Ittermann T, Haring R, Wallaschofski H, Baumeister SE, Nauck M, Dörr M, Lerch MM, Meyer zu Schwabedissen HE, Rosskopf D, Völzke H. Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania. Thyroid 2012; 22: 568-574 [PMID: 22574630 DOI: 10.1089/thy.2011.0279]
23. Eshraghian A, Dabbaghmanesh MH, Eshraghian H, Fattahi MR, Omrani GR. Nonalcoholic fatty liver disease in a cluster of Iranian population: thyroid status and metabolic risk factors. Arch Iran Med 2013; 16: 584-589 [PMID: 24093139]
24. Yilmaz Y. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis 2012; 32: 14-21 [PMID: 22418884 DOI: 10.1055/s-0032-1306422]
25. Collantes RS, Ong JP, Younossi ZM. The metabolic syndrome and nonalcoholic fatty liver disease. Panminerva Med 2006; 48: 41-48 [PMID: 16633331]
26. Pearce EN. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes 2012; 19: 408-413 [PMID: 22931855 DOI: 10.1097/MED.0b013e328355cd6c]
27. Pacifico L, Anania C, Ferraro F, Andreoli GM, Chiesa C. Thyroid function in childhood obesity and metabolic comorbidity. Clin Chim Acta 2012; 413: 396-405 [PMID: 22130312 DOI: 10.1016/j.cca.2011.11.013]
28. Waring AC, Rodondi N, Harrison S, Kanaya AM, Simonsick EM, Miljkovic I, Satterfield S, Newman AB, Bauer DC. Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing and Body Composition Study. Clin Endocrinol (Oxf) 2012; 76: 911-918 [PMID: 22187968 DOI: 10.1111/j.1365-2265.2011.04328.x]
29. Kowalska I, Borawski J, Nikołajuk A, Budlewski T, Otziomek E, Górska M, Stra{ogonek}czkowski M. Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy. Endocrine 2011; 40: 95-101 [PMID: 21424182 DOI: 10.1007/s12020-011-9446-5]
30. Smithson MJ. Screening for thyroid dysfunction in a community population of diabetic patients. Diabet Med 1998; 15: 148-150 [PMID: 9507916]
31. Díez JJ, Iglesias P. Subclinical hyperthyroidism in patients with type 2 diabetes. Endocrine 2012; 42: 157-163 [PMID: 22327927 DOI: 10.1007/s12020-012-9621-3]
32. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412-421 [PMID: 18081738]
33. Musso G, Gambino R, Durazzo M, Biroli G, Carello M, Fagà E, Pacini G, De Michieli F, Rabbione L, Premoli A, Cassader M, Pagano G. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42: 1175-1183 [PMID: 16231364]
34. Altinova AE, Törüner FB, Aktürk M, Bukan N, Cakir N, Ayvaz G, Arslan M. Adiponectin levels and cardiovascular risk factors in hypothyroidism and hyperthyroidism. Clin Endocrinol (Oxf) 2006; 65: 530-535 [PMID: 16984248]
35. Aragão CN, Souza LL, Cabanelas A, Oliveira KJ, Pazos-Moura CC. Effect of experimental hypo-and hyperthyroidism on serum adiponectin. Metabolism 2007; 56: 6-11 [PMID: 17161219]
36. Ozkaya M, Sahin M, Cakal E, Yuzbasioglu F, Sezer K, Kilinc M, Imrek SS. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. J Endocrinol Invest 2009; 32: 435-439 [PMID: 19498324 DOI: 10.3275/6296]
37. Caixàs A, Tirado R, Vendrell J, Gallart L, Megía A, Simón I, Llauradó G, González-Clemente JM, Giménez-Palop O. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 2009; 71: 733-738 [PMID: 19222486 DOI: 10.1111/ j.1365-2265.2009.03546.x]
38. Leonhardt U, Ritzel U, Schäfer G, Becker W, Ramadori G. Serum leptin levels in hypo-and hyperthyroidism. J Endocrinol 1998; 157: 75-79 [PMID: 9614360]
39. Kautzky-Willer A, Ludwig C, Nowotny P, Roden A, Huemer C, Widhalm K, Vierhapper H, Waldhäusl W, Roden M. Elevation of plasma leptin concentrations in obese hyperinsulinaemic hypothyroidism before and after treatment. Eur J Clin Invest 1999; 29: 395-403 [PMID: 10354196]
40. Oswal A, Yeo G. Leptin and the control of body weight: a review of its diverse central targets, signaling mechanisms, and role in the pathogenesis of obesity. Obesity (Silver Spring) 2010; 18: 221-229 [PMID: 19644451 DOI: 10.1038/ oby.2009.228]
41. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-771 [PMID: 11915021]
42. Benomar Y, Wetzler S, Larue-Achagiotis C, Djiane J, Tomé D, Taouis M. In vivo leptin infusion impairs insulin and leptin signalling in liver and hypothalamus. Mol Cell Endocrinol 2005; 242: 59-66 [PMID: 16150536]
43. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009; 48: 1-26 [PMID: 18824034 DOI: 10.1016/j.plipres.2008.08.001]
44. Hulbert AJ. Thyroid hormones and their effects: a new perspective. Biol Rev Camb Philos Soc 2000; 75: 519-631 [PMID: 11117200]
45. Grover GJ, Mellström K, Ye L, Malm J, Li YL, Bladh LG, Sleph PG, Smith MA, George R, Vennström B, Mookhtiar K, Horvath R, Speelman J, Egan D, Baxter JD. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 2003; 100: 10067-10072 [PMID: 12888625]
46. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD, Linemeyer DL. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007; 104: 15490-15495 [PMID: 17878314]
47. Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, Linemeyer DL, Erion MD. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009; 49: 407-417 [PMID: 19072834 DOI: 10.1002/hep.22572]
48. Brenta G, Berg G, Arias P, Zago V, Schnitman M, Muzzio ML, Sinay I, Schreier L. Lipoprotein alterations, hepatic lipase activity, and insulin sensitivity in subclinical hypothyroidism: response to L-T(4) treatment. Thyroid 2007; 17: 453-460 [PMID: 17542675]
49. Duntas LH. Thyroid disease and lipids. Thyroid 2002; 12: 287-293 [PMID: 12034052]
50. Reinehr T, Woelfle J, Wunsch R, Roth CL. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 2012; 97: 2143-2150 [PMID: 22438225 DOI: 10.1210/jc.2012-1221]
51. Kharitonenkov A, Shanafelt AB. FGF21: a novel prospect for the treatment of metabolic diseases. Curr Opin Investig Drugs 2009; 10: 359-364 [PMID: 19337957]
52. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-781 [PMID: 17068132]
53. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Véniant MM. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259 [PMID: 18840786 DOI: 10.2337/db08-0392]
54. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635 [PMID: 15902306]
55. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010; 53: 934-940 [PMID: 20675007 DOI: 10.1016/ j.jhep.2010.05.018]
56. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010; 40: 887-892 [PMID: 20624171 DOI: 10.1111/j.1365-2362.2010.02338.x]
57. Yan H, Xia M, Chang X, Xu Q, Bian H, Zeng M, Rao S, Yao X, Tu Y, Jia W, Gao X. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a crosssectional study. PLoS One 2011; 6: e24895 [PMID: 21949781 DOI: 10.1371/journal.pone.0024895]
58. Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011; 54: 3093-3100 [PMID: 21956711 DOI: 10.1007/ s00125-011-2317-z]
59. Adams AC, Astapova I, Fisher FM, Badman MK, Kurgansky KE, Flier JS, Hollenberg AN, Maratos-Flier E. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner. J Biol Chem 2010; 285: 14078-14082 [PMID: 20236931 DOI: 10.1074/jbc. C110.107375]
60. Lee Y, Park YJ, Ahn HY, Lim JA, Park KU, Choi SH, Park do J, Oh BC, Jang HC, Yi KH. Plasma FGF21 levels are increased in patients with hypothyroidism independently of lipid profile. Endocr J 2013; 60: 977-983 [PMID: 23759753]
61. D'Autréaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007; 8: 813-824 [PMID: 17848967]
62. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417: 1-13 [PMID: 19061483 DOI: 10.1042/BJ20081386]
63. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012; 52: 59-69 [PMID: 22064361 DOI: 10.1016/ j.freeradbiomed.2011.10.003]
64. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, Gentilini P, Dianzani MU. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 1993; 194: 1044-1050 [PMID: 8352762]
65. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008; 103: 1036-1042 [PMID: 18177455 DOI: 10.1111/ j.1572-0241.2007.01709.x]
66. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 1997; 11: 851-857 [PMID: 9285483]
67. Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk BO, Isbilen E, Tutuncu NB. Serum total antioxidant status and lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol (Oxf) 2009; 70: 469-474 [PMID: 18727709 DOI: 10.1111/ j.1365-2265.2008.03348.x]
68. Öztürk Ü, Vural P, Özderya A, Karadaǧ B, Doǧru-Abbasoǧlu S, Uysal M. Oxidative stress parameters in serum and low density lipoproteins of Hashimoto's thyroiditis patients with subclinical and overt hypothyroidism. Int Immunopharmacol 2012; 14: 349-352 [PMID: 22951187 DOI: 10.1016/j.intimp]
69. Baskol G, Atmaca H, Tanriverdi F, Baskol M, Kocer D, Bayram F. Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment. Exp Clin Endocrinol Diabetes 2007; 115: 522-526 [PMID: 17853336]